BioCrossroads names two new executives
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
BioCrossroads, Indiana’s initiative to grow the life sciences sector, has added two new people to the organization’s leadership team. Jane Dunigan-Smith will serve as senior vice president, chief strategy officer and managing director of Seed Funds, and Mike Bolinder was named SVP of external engagement, and chief innovation officer.
Dunigan-Smith most recently worked for Indianapolis-based Eli Lilly and Co. (NYSE: LLY), where she was involved in commercialization, corporate strategy and operations. She also has a background in accounting and finance.
“Jane’s multi-faceted experience positions her to manage the Seed Funds and lead our strategy at a time when Indiana’s life sciences sector is expanding and innovating in multiple areas,” said BioCrossroads President and CEO Patty Martin. “Her experience in pharmaceutical commercialization will be key as we develop strategic plans to support other promising sub-sectors while continuing to support our already established strengths in pharmaceuticals and biologics, medical devices and equipment, medical, research and testing laboratories and contract manufacturing organizations.”
Bolinder has worked in the life sciences sector for 20 years. Most recently he was CEO and executive director of Acacia Pharma Group plc, a publicly listed group of companies with headquarters in both Indianapolis and Cambridge, UK.
Bolinder also spent time at Lilly.
“Mike has an ideal combination of experience working with large corporate and start-up entities to make an immediate impact through BioCrossroads,” said Martin. “There are so many opportunities ahead to continue to grow this sector, and he will be able to utilize his knowledge and experience to make some great things happen.”
Meanwhile, Martin will step down next month from BioCrossroads. She’s been CEO since 2019.